Resistance associated substitutions and genotypes/subtypes in direct-acting antivirals (DAAs) agents non-responding hepatitis C virus (HCV) infected patients
| DAA | Amino acid substitutions detected in DAA failing patients | HCV genotype/subtype associated with SVR failure |
|---|---|---|
| SOF | 159F | 1a, 1b, 2a/b/c, 3a |
| 237G | 1a, 3a, 4a/d | |
| 282R/G/T | 1a, 1b, 2a/b/c, 3a, 4a/d | |
| 316F/H/N | 1a, 1b | |
| 320F | 1a | |
| 321A/I | 1a, 1b, 3a, 4a/d | |
| VEL | 24R | 1a |
| 28T/V | 1a | |
| 30E/K/H/V/K/L/R | 1a, 3a | |
| 31M/V/P | 1a, 1b, 2a/b/c, 3a, 4a/d | |
| 32L | 1a | |
| 58D | 1a | |
| 92K | 3a | |
| 93H/N/R/S/T/W | 1a, 1b, 2a/b/c, 3a, 4a/d | |
| VOX | 36L | 1a |
| 43S | 1b | |
| 80K/R | 1a, 4a/d | |
| 156T/V | 1a,1b |
SOF: sofosbuvir, NS5B-polymerase inhibitor; VEL: velpatasvir, 2nd generation of NS5A inhibitor; VOX: voxilaprevir, 2nd generation of protease inhibitor; SVR: sustained virological response